AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27585415 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg intranasal midazolam (INM)
Number of subjects: 118
Study 27585415 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg intranasal midazolam (INM)
Number of subjects: 118
Study 24662619 — intervention group
Group type: EXPERIMENTAL
Intervention: Undercarboxylated osteocalcin (ucOC%)
Number of subjects: 0
Study 24662619 — intervention group
Group type: EXPERIMENTAL
Intervention: Total osteocalcin (tOC)
Number of subjects: 0
Study 22237121 — intervention group
Group type: EXPERIMENTAL
Intervention: Feiji Decoction for soothing the liver combined with psychotherapy and chemotherapy
Number of subjects: 118
Study 22237121 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy only
Number of subjects: 118
Study 19560290 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil 200mg
Number of subjects: 210
Study 19560290 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil 400mg
Number of subjects: 210
Study 19560290 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210
Study 16810542 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative autologous blood reinfusion system (group A)
Number of subjects: 60
Study 16810542 — intervention group
Group type: COMPARATOR
Intervention: Standard suction drains with homologous banked blood transfusion (group B)
Number of subjects: 60
Study 15192274 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN alpha‐2b
Number of subjects: 49
Study 15192274 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐IFN alpha‐2b
Number of subjects: 49
Study 11825635 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumption of fruits
Number of subjects: 40
Study 11825635 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumption of vegetables
Number of subjects: 40
Study 11825635 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumption of soft drinks
Number of subjects: 40
Study 11825635 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumption of high-fat-containing snacks
Number of subjects: 40
Study 9832107 — intervention group
Group type: EXPERIMENTAL
Intervention: >1 mg nicotine (group 1)
Number of subjects: 21
Study 9832107 — intervention group
Group type: EXPERIMENTAL
Intervention: <1 mg nicotine (group 2)
Number of subjects: 21
Study 9832107 — intervention group
Group type: COMPARATOR
Intervention: Control group (mimicked smoking without a cigarette)
Number of subjects: 21
Study 7857162 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline sulfate in combination with cefotaxime
Number of subjects: 0
Study 2683548 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepivacaine 2%
Number of subjects: 3
Study 2683548 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5%
Number of subjects: 3
Study 2683548 — intervention group
Group type: EXPERIMENTAL
Intervention: Etidocaine 1.5%
Number of subjects: 3
Study 2683548 — intervention group
Group type: EXPERIMENTAL
Intervention: All three local anaesthetics
Number of subjects: 3
Study 782679 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate aerosol (BDA), 50 mug four times daily in each nostril
Number of subjects: 30
Study 782679 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 30
Study 31558549 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarker screening and genetic testing
Number of subjects: 0
Study 31558549 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarker screening and genetic testing with cascade genetic testing
Number of subjects: 0
Study 31558549 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 27904911 — intervention group
Group type: EXPERIMENTAL
Intervention: Bihemispheric anodal tDCS with conventional swallowing therapy
Number of subjects: 26
Study 27904911 — intervention group
Group type: COMPARATOR
Intervention: Sham group
Number of subjects: 26
Study 26003889 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin add-on (50 mg twice a day)
Number of subjects: 344
Study 26003889 — intervention group
Group type: COMPARATOR
Intervention: Sulfonylurea dose-increasing by 50%
Number of subjects: 344
Study 26003889 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin add-on
Number of subjects: 344
Study 26003889 — intervention group
Group type: COMPARATOR
Intervention: Sulfonylurea dose-increasing
Number of subjects: 344
Study 23755215 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-infected individuals (ALLRT cohort)
Number of subjects: 0
Study 23755215 — intervention group
Group type: COMPARATOR
Intervention: HIV-uninfected persons (NHANES cohort)
Number of subjects: 0
Study 21795635 — intervention group
Group type: COMPARATOR
Intervention: Combined bolus infusion of GH or saline and continuous stimulation by saline GH‐releasing hormone (GHRH), GHRP‐2, or both peptides after randomly ordered supplementation with placebo vs. E(2) (estrogen; women) and T (testosterone; men)
Number of subjects: 25
Study 21795635 — intervention group
Group type: EXPERIMENTAL
Intervention: Peptidyl secretagog
Number of subjects: 25
Study 21795635 — intervention group
Group type: EXPERIMENTAL
Intervention: IGF‐I
Number of subjects: 25
Study 21795635 — intervention group
Group type: EXPERIMENTAL
Intervention: Body mass index
Number of subjects: 25
Study 19698059 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 756
Study 19698059 — intervention group
Group type: COMPARATOR
Intervention: NPH insulin
Number of subjects: 756
Study 16936418 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intravenous and intracoronary administration of nicorandil (Group B)
Number of subjects: 92
Study 16936418 — intervention group
Group type: COMPARATOR
Intervention: No nicorandil administration (Group C)
Number of subjects: 92
Study 14614600 — intervention group
Group type: EXPERIMENTAL
Intervention: lansoprazole
Number of subjects: 64
Study 14614600 — intervention group
Group type: EXPERIMENTAL
Intervention: ecabet sodium
Number of subjects: 64
Study 14614600 — intervention group
Group type: EXPERIMENTAL
Intervention: rebamipide
Number of subjects: 64
Study 14614600 — intervention group
Group type: EXPERIMENTAL
Intervention: nizatidine
Number of subjects: 64
Study 14614600 — intervention group
Group type: EXPERIMENTAL
Intervention: polaprezinc
Number of subjects: 64
Study 14614600 — intervention group
Group type: EXPERIMENTAL
Intervention: teprenone
Number of subjects: 64
Study 14614600 — intervention group
Group type: EXPERIMENTAL
Intervention: cetraxate hydrochloride
Number of subjects: 64
Study 14614600 — intervention group
Group type: EXPERIMENTAL
Intervention: sucralfate
Number of subjects: 64
Study 10732535 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week home-based exercise program
Number of subjects: 0
Study 10732535 — intervention group
Group type: COMPARATOR
Intervention: No exercise (control group)
Number of subjects: 0
Study 8618155 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation
Number of subjects: 40
Study 8618155 — intervention group
Group type: COMPARATOR
Intervention: Voluntary contraction
Number of subjects: 40
Study 1399930 — intervention group
Group type: EXPERIMENTAL
Intervention: Aztreonam/vancomycin
Number of subjects: 36
Study 1399930 — intervention group
Group type: COMPARATOR
Intervention: Piperacillin/gentamicin
Number of subjects: 36
Study 4044346 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose per fraction radiotherapy at 9 Gy X 3
Number of subjects: 14
Study 4044346 — intervention group
Group type: COMPARATOR
Intervention: High dose per fraction radiotherapy at 5 Gy X 8 twice weekly
Number of subjects: 14
Study 30099973 — intervention group
Group type: EXPERIMENTAL
Intervention: Volunteer intervention (1:1 person‐centered care with a focus on nutrition and hydration support, hearing and visual aids, activities, and orientation)
Number of subjects: 458
Study 30099973 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients admitted 12 months prior to the volunteer program)
Number of subjects: 458
Study 30099973 — intervention group
Group type: EXPERIMENTAL
Intervention: Volunteer intervention
Number of subjects: 458
Study 27871505 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex (2-4 mg · kg‐1) after deep neuromuscular block with 0.6 mg · kg‐1 rocuronium
Number of subjects: 100
Study 27871505 — intervention group
Group type: COMPARATOR
Intervention: Neostigmine (50 μg · kg‐1) after shallow neuromuscular block with 0.45 mg · kg‐1 rocuronium
Number of subjects: 100
Study 27871505 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex (2-4 mg · kg‐1)
Number of subjects: 100
Study 27871505 — intervention group
Group type: COMPARATOR
Intervention: Neostigmine (50 μg · kg‐1)
Number of subjects: 100
Study 25189164 — intervention group
Group type: EXPERIMENTAL
Intervention: sipuleucel-T
Number of subjects: 377
Study 22820319 — intervention group
Group type: EXPERIMENTAL
Intervention: Palivizumab (one-monthly intramuscular injections during RSV season, minimum of 2 injections)
Number of subjects: 0
Study 22820319 — intervention group
Group type: COMPARATOR
Intervention: Placebo (one-monthly intramuscular injections during RSV season, minimum of 2 injections)
Number of subjects: 0
Study 22820319 — intervention group
Group type: EXPERIMENTAL
Intervention: Palivizumab
Number of subjects: 0
Study 22820319 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22820319 — intervention group
Group type: EXPERIMENTAL
Intervention: Palivizumab and Placebo
Number of subjects: 0
Study 20444625 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticlopidine
Number of subjects: 1809
Study 20444625 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 1809
Study 18827610 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral topotecan (OT) with best supportive care
Number of subjects: 141
Study 18827610 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care alone
Number of subjects: 141
Study 16376650 — intervention group
Group type: EXPERIMENTAL
Intervention: Foldable silicone, sharp optic edge IOL
Number of subjects: 53
Study 16376650 — intervention group
Group type: COMPARATOR
Intervention: Silicone, rounded optic edge IOL
Number of subjects: 53
Study 16376650 — intervention group
Group type: COMPARATOR
Intervention: Acrylate, sharp optic edge IOL
Number of subjects: 53
Study 11954700 — intervention group
Group type: EXPERIMENTAL
Intervention: PCA + fuzzy logic control (FLC)
Number of subjects: 25
Study 11954700 — intervention group
Group type: COMPARATOR
Intervention: Conventional PCA
Number of subjects: 25
Study 9542558 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 20 micrograms.kg‐1
Number of subjects: 100
Study 9542558 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 40 micrograms.kg‐1
Number of subjects: 100
Study 9542558 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 80 micrograms.kg‐1
Number of subjects: 100
Study 9542558 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 100
Study 7534966 — intervention group
Group type: EXPERIMENTAL
Intervention: fetal fibronectin (fFN)
Number of subjects: 131
Study 7534966 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha-fetoprotein (AFP)
Number of subjects: 131
Study 7534966 — intervention group
Group type: EXPERIMENTAL
Intervention: diamino-oxydase (DAO)
Number of subjects: 131
Study 2198072 — intervention group
Group type: EXPERIMENTAL
Intervention: Exploratory therapy (relationship-oriented)
Number of subjects: 120
Study 2198072 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescriptive therapy (cognitive/behavioural)
Number of subjects: 120
Study 2198072 — intervention group
Group type: EXPERIMENTAL
Intervention: Eight sessions of therapy
Number of subjects: 120
Study 2198072 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 sessions of therapy
Number of subjects: 120
Study 387000 — intervention group
Group type: EXPERIMENTAL
Intervention: DL-phenylalanine (150-200 mg/24 h)
Number of subjects: 40
Study 387000 — intervention group
Group type: COMPARATOR
Intervention: Imipramine (150-200 mg/24 h)
Number of subjects: 40
Study 31870394 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based preventive intervention including screening for hypertension, diabetes, and stroke, followed by referral to a mobile outreach clinic, guideline-based treatment, monthly home visits by CHWs for medication compliance, and counseling on reducing salt consumption and quitting tobacco and alcohol.
Number of subjects: 32
Study 31870394 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care (EUC) arm providing information on the ill effects of tobacco use and steps to quit, with access to the government's national programme for the prevention and control of non-communicable diseases.
Number of subjects: 32
Study 28952325 — intervention group
Group type: EXPERIMENTAL
Intervention: Text message intervention for 9 months
Number of subjects: 67
Study 28952325 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 67
Study 28492194 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine (0.12%) mouth rinse
Number of subjects: 75
Study 28492194 — intervention group
Group type: COMPARATOR
Intervention: Combination mouth rinse (chlorhexidine and sodium fluoride)
Number of subjects: 75
Study 28492194 — intervention group
Group type: COMPARATOR
Intervention: Green tea extract (0.5%) mouth rinse
Number of subjects: 75
Study 25673557 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk (500 ml) - Female
Number of subjects: 32
Study 25673557 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk (500 ml) - Male
Number of subjects: 32
Study 25673557 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate (500 ml) - Female
Number of subjects: 32
Study 25673557 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate (500 ml) - Male
Number of subjects: 32
Study 23098696 — intervention group
Group type: EXPERIMENTAL
Intervention: Swedish massage
Number of subjects: 54
Study 23098696 — intervention group
Group type: COMPARATOR
Intervention: Touch (control group)
Number of subjects: 54
Study 23098696 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 54
Study 20415916 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass ionomer cement (GIC)
Number of subjects: 0
Study 20415916 — intervention group
Group type: COMPARATOR
Intervention: Calcium hydroxide (Ca(OH)(2)) lining cement
Number of subjects: 0
Study 19317162 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziyin Tongbi Decoction (ZTD), one dose per day, consisting of various herbal ingredients, taken twice daily (150 mL each time) for 4 weeks
Number of subjects: 100
Study 19317162 — intervention group
Group type: COMPARATOR
Intervention: Longbishu Capsule, 0.9 g each time, taken twice a day for 4 weeks
Number of subjects: 100
Study 16365065 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (5 mL daily for 3 months)
Number of subjects: 83
Study 12573743 — intervention group
Group type: EXPERIMENTAL
Intervention: Altered fractionation in radiotherapy (EORTC 22851 and CHART trials)
Number of subjects: 2566
Study 12573743 — intervention group
Group type: COMPARATOR
Intervention: Conventional fractionation in radiotherapy (EORTC 22851 and CHART trials)
Number of subjects: 2566
Study 12573743 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperfractionation in radiotherapy (PMH trial)
Number of subjects: 2566
Study 12573743 — intervention group
Group type: COMPARATOR
Intervention: Conventional fractionation in radiotherapy (PMH trial)
Number of subjects: 2566
Study 12573743 — intervention group
Group type: EXPERIMENTAL
Intervention: Compliance to prescribed radiation therapy schedule
Number of subjects: 2566
Study 12573743 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent treatment compliance
Number of subjects: 2566
Study 11132811 — intervention group
Group type: EXPERIMENTAL
Intervention: AIM-dyad condition
Number of subjects: 108
Study 11132811 — intervention group
Group type: COMPARATOR
Intervention: Individual control training condition
Number of subjects: 108
Study 9372795 — intervention group
Group type: EXPERIMENTAL
Intervention: NaF toothpaste containing 1500 ppm fluoride
Number of subjects: 4196
Study 9372795 — intervention group
Group type: COMPARATOR
Intervention: NaF toothpaste containing 1000 ppm fluoride
Number of subjects: 4196
Study 9372795 — intervention group
Group type: EXPERIMENTAL
Intervention: NaF toothpaste with trimetaphosphate (TMP)
Number of subjects: 4196
Study 9372795 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects brushing more frequently
Number of subjects: 4196
Study 9372795 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects not using a tumbler to rinse after toothbrushing
Number of subjects: 4196
Study 10126852 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical pharmacists' consultations
Number of subjects: 236
Study 2861311 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (hydrochlorothiazide + triamterene)
Number of subjects: 840
Study 2861311 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 840
Study 30456564 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D (50,000 IU/week)
Number of subjects: 96
Study 30456564 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 30369600 — intervention group
Group type: EXPERIMENTAL
Intervention: Advance Care Planning (ACP) intervention
Number of subjects: 208
Study 30369600 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 208
Study 26652811 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasoduodenal (ND) feeding
Number of subjects: 40
Study 26652811 — intervention group
Group type: COMPARATOR
Intervention: Nasogastric (NG) feeding
Number of subjects: 40
Study 25034003 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% sodium cromoglicate cutaneous emulsion
Number of subjects: 208
Study 25034003 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 208
Study 22930120 — intervention group
Group type: COMPARATOR
Intervention: No past year alcohol use (AUDIT‐C 0)
Number of subjects: 3930
Study 22930120 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level alcohol use (AUDIT‐C 1-3)
Number of subjects: 3930
Study 22930120 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild alcohol misuse (AUDIT‐C 4-5)
Number of subjects: 3930
Study 22930120 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate alcohol misuse (AUDIT‐C 6-7)
Number of subjects: 3930
Study 22930120 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe alcohol misuse (AUDIT‐C 8-12)
Number of subjects: 3930
Study 21054297 — intervention group
Group type: EXPERIMENTAL
Intervention: Environmental barriers (lack of resting places, long distances, noisy traffic, dangerous crossroads, hilly terrain, poor street condition)
Number of subjects: 589
Study 21054297 — intervention group
Group type: EXPERIMENTAL
Intervention: Fear of moving outdoors
Number of subjects: 589
Study 21054297 — intervention group
Group type: EXPERIMENTAL
Intervention: Unmet physical activity need
Number of subjects: 589
Study 21054297 — intervention group
Group type: EXPERIMENTAL
Intervention: Slower walking speed
Number of subjects: 589
Study 21054297 — intervention group
Group type: EXPERIMENTAL
Intervention: More chronic diseases
Number of subjects: 589
Study 21054297 — intervention group
Group type: EXPERIMENTAL
Intervention: Environmental barriers, fear of moving outdoors, unmet physical activity need
Number of subjects: 589
Study 21054297 — intervention group
Group type: EXPERIMENTAL
Intervention: Distances
Number of subjects: 589
Study 18525001 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferumoxytol (two 510‐mg doses of intravenous ferumoxytol within 5 +/- 3 days)
Number of subjects: 304
Study 18525001 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferumoxytol (among patients not receiving erythropoiesis-stimulating agents)
Number of subjects: 304
Study 18525001 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferumoxytol (among patients receiving erythropoiesis-stimulating agents)
Number of subjects: 304
Study 18525001 — intervention group
Group type: COMPARATOR
Intervention: Oral iron (200 mg of elemental oral iron daily for 21 days)
Number of subjects: 304
Study 18525001 — intervention group
Group type: COMPARATOR
Intervention: Oral iron (among patients not receiving erythropoiesis-stimulating agents)
Number of subjects: 304
Study 18525001 — intervention group
Group type: COMPARATOR
Intervention: Oral iron (among patients receiving erythropoiesis-stimulating agents)
Number of subjects: 304
Study 18525001 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferumoxytol
Number of subjects: 304
Study 18525001 — intervention group
Group type: COMPARATOR
Intervention: Oral iron
Number of subjects: 304
Study 15784705 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring system (CGMS)
Number of subjects: 200
Study 15784705 — intervention group
Group type: COMPARATOR
Intervention: Eight-point testing
Number of subjects: 200
Study 12208563 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (n=26)
Number of subjects: 52
Study 12208563 — intervention group
Group type: COMPARATOR
Intervention: Waiting list (n=26)
Number of subjects: 52
Study 10734504 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 136
Study 7727815 — intervention group
Group type: EXPERIMENTAL
Intervention: Mupirocin nasal ointment
Number of subjects: 54
Study 7727815 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 3121830 — intervention group
Group type: EXPERIMENTAL
Intervention: High heparin dose (137.3 U/day) during 15-hour lipid infusion
Number of subjects: 22
Study 3121830 — intervention group
Group type: COMPARATOR
Intervention: Low heparin dose (24 U/day) infused over 24 hours
Number of subjects: 22
Study 3121830 — intervention group
Group type: EXPERIMENTAL
Intervention: Both heparin doses at either infusion rate
Number of subjects: 22
Study 30717757 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIT) (4 min at 85-95% of peak HRR, 3 days a week for 12 weeks)
Number of subjects: 21
Study 30717757 — intervention group
Group type: COMPARATOR
Intervention: Moderate Continuous Training (MCT) (60-75% of heart rate reserve, 3 days a week for 12 weeks)
Number of subjects: 21
Study 30717757 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIT)
Number of subjects: 21
Study 30717757 — intervention group
Group type: COMPARATOR
Intervention: Moderate Continuous Training (MCT)
Number of subjects: 21
Study 27696933 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flavanol and high-theobromine (HFHT) chocolate (30 grams daily for 12 weeks)
Number of subjects: 131
Study 27696933 — intervention group
Group type: COMPARATOR
Intervention: Low-flavanol and low-theobromine (LFLT) chocolate (30 grams daily for 12 weeks)
Number of subjects: 131